NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 03/30/2020 14:36
Last Report Issued 01/30/2013 14:44

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 9546SP-POS
Patient ID 9546SP-POS
Chain 13000635
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 13000635

Received 01/30/2013 12:48

Sample ID 13000635-001
Matrix Serum or Plasma
Patient Name 9546SP-POS
Patient ID 9546SP-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
9546SP Hydrochlorothiazide Screen (Add-On), Serum/Plasma (Forensic) (CSA)				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Hydrochlorothiazide	See Comment	ng/mL	25	
Synonym(s): Microzide®				
Comment: Based on this screening result, confirmation testing was performed. Refer to the confirmation test result(s).				
52156SP Hydrochlorothiazide Confirmation, Serum/Plasma (CSA)				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Hydrochlorothiazide	500	ng/mL	25	ELEVATED
Synonym(s): Microzide®				

Results for sample 13000635-001 are continued on next page

NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Sample ID 13000635-001
Matrix Serum or Plasma
Patient Name 9546SP-POS
Patient ID 9546SP-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
Daily administration of oral hydrochlorothiazide produced the following plasma concentrations in hypertensive patients: 25 mg = 17 +/-8 ng/mL trough and 76 +/- 26 ng/mL 5 hours post dose 75 mg = 34 +/- 17 ng/mL trough and 200 +/- 93 ng/mL 5 hours post dose.				

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.